A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Ohshima Hosoyama, Sachiko ^a   Simmons, Heather A ^a   Goecks, Nichole ^a   Joers, Valerie ^a,b   Swanson, Christine R ^a,b   Bondarenko, Viktoriya ^a   Velotta, Rebecca ^a   Brunner, Kevin ^a   Wood, Laura D ^d   Hruban, Ralph H ^d   Emborg, Marina E ^a,b,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MONOCLONAL ANTIBODY GDNF; UNCLASSIFIED DRUG;

ACINAR CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; MALE; METAPLASIA; MOTOR PERFORMANCE; MYOCARDITIS; NEUROPROTECTION; NONHUMAN; PANCREAS ADENOMA; PANCREAS DUCT; PARKINSON DISEASE; PARKINSONISM; RATING SCALE; RHESUS MONKEY; SUBSTANTIA NIGRA; TOXIC HEPATITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MACACA MULATTA; MALE; PANCREATIC NEOPLASMS; PARKINSON DISEASE; RECOMBINANT FUSION PROTEINS;

EID: 84862653625     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039036     Document Type: Article

References (50)

1. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F, (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
2. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, et al. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252-255.
3. Kirik D, Georgievska B, Bjorklund A, (2004) Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 7: 105-110.
4. Moretto G, Walker DG, Lanteri P, Taioli F, Zaffagnini S, et al. (1996) Expression and regulation of glial-cell-line-derived neurotrophic factor (GDNF) mRNA in human astrocytes in vitro. Cell Tissue Res 286: 257-262.
5. Grondin R, Zhang Z, Yi A, Cass WA, Maswood N, et al. (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125: 2191-2201.
6. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290: 767-773.
7. Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, et al. (2005) Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25: 769-777.
8. Emborg ME, Moirano J, Raschke J, Bondarenko V, Zufferey R, et al. (2009) Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 36: 303-311.
9. Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, et al. (2009) Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 20: 511-518.
10. Emborg ME, Ebert AD, Moirano J, Peng S, Suzuki M, et al. (2008) GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys. Cell Transplant 17: 383-395.
11. Capowski EE, Schneider BL, Ebert AD, Seehus CR, Szulc J, et al. (2007) Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy. J Neurosci Methods 163: 338-349.
12. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, et al. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589-595.
13. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466.
14. Kimmelman J, London AJ, Ravina B, Ramsay T, Bernstein M, et al. (2009) Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations. Mov Disord 24: 1893-1901.
15. Boado RJ, Zhang Y, Wang Y, Pardridge WM, (2008) GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol Bioeng 100: 387-396.
16. Vastag B, (2010) Biotechnology: Crossing the barrier. Nature 466: 916-918.
17. Fu A, Zhou QH, Hui EK, Lu JZ, Boado RJ, et al. (2010) Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res 1352: 208-213.
18. Emborg-Knott ME, Domino EF, (1998) MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose. Exp Neurol 152: 214-220.
19. Emborg ME, Shin P, Roitberg B, Sramek JG, Chu Y, et al. (2001) Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp Neurol 168: 171-182.
20. Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, et al. (2011) The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation.
21. Boado RJ, Pardridge WM, (2009) Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab Dispos 37: 2299-2304.
22. Pardridge WM, Boado RJ, (2009) Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm Res 26: 2227-2236.
23. Hartmann M, Bode C, Zirlik A, (2008) Anaphylactic shock-associated cardiomyopathy. Int J Cardiol 127: e136-137.
24. Hiltunen JO, Laurikainen A, Airaksinen MS, Saarma M, (2000) GDNF family receptors in the embryonic and postnatal rat heart and reduced cholinergic innervation in mice hearts lacking ret or GFRalpha2. Dev Dyn 219: 28-39.
25. Bar RS, Boes M, Sandra A, (1988) Vascular transport of insulin to rat cardiac muscle. Central role of the capillary endothelium. J Clin Invest 81: 1225-1233.
26. Depner CM, Kirwan RD, Frederickson SJ, Miles MP, (2010) Enhanced inflammation with high carbohydrate intake during recovery from eccentric exercise. Eur J Appl Physiol 109: 1067-1076.
27. Simmons HA, Mattison JA, (2011) The incidence of spontaneous neoplasia in two populations of captive rhesus macaques (Macaca mulatta). Antioxid Redox Signal 14: 221-227.
28. Hruban RH, Pitman MB, Klimstra DS, (2007) Tumors of the Pancreas. Washington, DC: American Registry of Pathology. 422 p.
29. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, et al. (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291-302.
30. Carriere C, Seeley ES, Goetze T, Longnecker DS, Korc M, (2007) The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A 104: 4437-4442.
31. Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF, (2007) Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol 171: 263-273.
32. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH, (1998) Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 22: 163-169.
33. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, et al. (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25: 579-586.
34. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, et al. (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28: 977-987.
35. Hovland DN Jr, Boyd RB, Butt MT, Engelhardt JA, Moxness MS, et al. (2007) Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol 35: 1013-1029.
36. Okada Y, Takeyama H, Sato M, Morikawa M, Sobue K, et al. (1999) Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF). Int J Cancer 81: 67-73.
37. Ito Y, Okada Y, Sato M, Sawai H, Funahashi H, et al. (2005) Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. Surgery 138: 788-794.
38. Sawai H, Okada Y, Kazanjian K, Kim J, Hasan S, et al. (2005) The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 65: 11536-11544.
39. Gil Z, Cavel O, Kelly K, Brader P, Rein A, et al. (2010) Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J Natl Cancer Inst 102: 107-118.
40. Watanabe M, Hayasaki H, Tamayama T, Shimada M, (1998) Histologic distribution of insulin and glucagon receptors. Braz J Med Biol Res 31: 243-256.
41. Sakamoto C, Williams JA, Roach E, Goldfine ID, (1984) In vivo localization of insulin binding to cells of the rat pancreas. Proc Soc Exp Biol Med 175: 497-502.
42. Emborg ME, (2007) Nonhuman primate models of Parkinson's disease. ILAR J 48: 339-355.
43. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, et al. (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76: 1265-1274.
44. Emborg ME, Moirano J, Schafernak KT, Moirano M, Evans M, et al. (2006) Basal ganglia lesions after MPTP administration in rhesus monkeys. Neurobiol Dis 23: 281-289.
45. Emborg ME, Moirano J, Raschke J, Bondarenko V, Zuffrey RZ, et al. (2009) Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 36: 303-311.
46. Emborg ME, Ma SY, Mufson EJ, Levey AI, Taylor MD, et al. (1998) Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401: 253-265.
47. Emborg ME, Moirano J, Schafernak KT, Moirano M, Evans M, et al. (2006) Basal ganglia lesions after MPTP administration in rhesus monkeys. Neurobiol Dis 23: 281-289.
48. Emborg ME, Ma SY, Mufson EJ, Levee A, Holden JE, et al. (1998) Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401.
49. West MJ, Ostergaard K, Andreassen OA, Finsen B, (1996) Estimation of the number of somatostatin neurons in the striatum: an in situ hybridization study using the optical fractionator method. J Comp Neurol 370.
50. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H, (1991) The absolutely number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54.